The state of hepatic artery infusion chemotherapy in the management of metastatic colorectal cancer to the liver

Marcia Leung, Sepideh Gholami

Research output: Contribution to journalReview article

Abstract

Hepatic artery infusion (HAI) chemotherapy is a locoregional therapy for colorectal cancer liver metastasis that has been available since the 1980s. Multiple clinical trials have demonstrated the safety and efficacy of HAI with higher response rates compared to systemic chemotherapy alone. Clinical trials have shown the benefit of using HAI as a bridge to conversion to resection at a higher rate than systemic chemotherapy alone with rates as high as 60% in heavily pretreated patients. HAI in combination with systemic chemotherapy has also been associated with prolonged recurrence free survival and overall survival in the adjuvant setting. Specifically, the addition of HAI continues to show a benefit in prolonging overall survival, despite increased effectiveness of modern systemic chemotherapy (i.e., oxaliplatin and irinotecan). Lower recurrence and improved survival rates associated with HAI and systemic chemotherapy persist regardless of RAS mutational status.

Original languageEnglish (US)
Article number54
JournalChinese Clinical Oncology
Volume8
Issue number5
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hepatic Artery
Liver Neoplasms
Colorectal Neoplasms
Drug Therapy
oxaliplatin
irinotecan
Survival
Clinical Trials
Recurrence
Survival Rate
Neoplasm Metastasis
Safety

Keywords

  • Biological tumor markers
  • Cancer chemotherapy agents
  • Colorectal cancer metastasis
  • Locoregional liver therapy

ASJC Scopus subject areas

  • Oncology

Cite this

The state of hepatic artery infusion chemotherapy in the management of metastatic colorectal cancer to the liver. / Leung, Marcia; Gholami, Sepideh.

In: Chinese Clinical Oncology, Vol. 8, No. 5, 54, 01.01.2019.

Research output: Contribution to journalReview article

@article{7d99290c1a914413b3a4cd1ed39ebeee,
title = "The state of hepatic artery infusion chemotherapy in the management of metastatic colorectal cancer to the liver",
abstract = "Hepatic artery infusion (HAI) chemotherapy is a locoregional therapy for colorectal cancer liver metastasis that has been available since the 1980s. Multiple clinical trials have demonstrated the safety and efficacy of HAI with higher response rates compared to systemic chemotherapy alone. Clinical trials have shown the benefit of using HAI as a bridge to conversion to resection at a higher rate than systemic chemotherapy alone with rates as high as 60{\%} in heavily pretreated patients. HAI in combination with systemic chemotherapy has also been associated with prolonged recurrence free survival and overall survival in the adjuvant setting. Specifically, the addition of HAI continues to show a benefit in prolonging overall survival, despite increased effectiveness of modern systemic chemotherapy (i.e., oxaliplatin and irinotecan). Lower recurrence and improved survival rates associated with HAI and systemic chemotherapy persist regardless of RAS mutational status.",
keywords = "Biological tumor markers, Cancer chemotherapy agents, Colorectal cancer metastasis, Locoregional liver therapy",
author = "Marcia Leung and Sepideh Gholami",
year = "2019",
month = "1",
day = "1",
doi = "10.21037/cco.2019.09.01",
language = "English (US)",
volume = "8",
journal = "Chinese Clinical Oncology",
issn = "2304-3865",
publisher = "Society for Translational Medicine (STM)",
number = "5",

}

TY - JOUR

T1 - The state of hepatic artery infusion chemotherapy in the management of metastatic colorectal cancer to the liver

AU - Leung, Marcia

AU - Gholami, Sepideh

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hepatic artery infusion (HAI) chemotherapy is a locoregional therapy for colorectal cancer liver metastasis that has been available since the 1980s. Multiple clinical trials have demonstrated the safety and efficacy of HAI with higher response rates compared to systemic chemotherapy alone. Clinical trials have shown the benefit of using HAI as a bridge to conversion to resection at a higher rate than systemic chemotherapy alone with rates as high as 60% in heavily pretreated patients. HAI in combination with systemic chemotherapy has also been associated with prolonged recurrence free survival and overall survival in the adjuvant setting. Specifically, the addition of HAI continues to show a benefit in prolonging overall survival, despite increased effectiveness of modern systemic chemotherapy (i.e., oxaliplatin and irinotecan). Lower recurrence and improved survival rates associated with HAI and systemic chemotherapy persist regardless of RAS mutational status.

AB - Hepatic artery infusion (HAI) chemotherapy is a locoregional therapy for colorectal cancer liver metastasis that has been available since the 1980s. Multiple clinical trials have demonstrated the safety and efficacy of HAI with higher response rates compared to systemic chemotherapy alone. Clinical trials have shown the benefit of using HAI as a bridge to conversion to resection at a higher rate than systemic chemotherapy alone with rates as high as 60% in heavily pretreated patients. HAI in combination with systemic chemotherapy has also been associated with prolonged recurrence free survival and overall survival in the adjuvant setting. Specifically, the addition of HAI continues to show a benefit in prolonging overall survival, despite increased effectiveness of modern systemic chemotherapy (i.e., oxaliplatin and irinotecan). Lower recurrence and improved survival rates associated with HAI and systemic chemotherapy persist regardless of RAS mutational status.

KW - Biological tumor markers

KW - Cancer chemotherapy agents

KW - Colorectal cancer metastasis

KW - Locoregional liver therapy

UR - http://www.scopus.com/inward/record.url?scp=85073102307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073102307&partnerID=8YFLogxK

U2 - 10.21037/cco.2019.09.01

DO - 10.21037/cco.2019.09.01

M3 - Review article

C2 - 31597435

AN - SCOPUS:85073102307

VL - 8

JO - Chinese Clinical Oncology

JF - Chinese Clinical Oncology

SN - 2304-3865

IS - 5

M1 - 54

ER -